VKTX - Viking Therapeutics, Inc.
| Previous Close | 6.95 |
| Open | 7.02 |
| Bid | 7.30 x 2200 |
| Ask | 7.34 x 1400 |
| Day's Range | 6.96 - 7.34 |
| 52 Week Range | 6.15 - 11.03 |
| Volume | 1,331,246 |
| Avg. Volume | 1,437,661 |
| Market Cap | 530.414M |
| Beta (3Y Monthly) | 2.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.33 |
| Earnings Date | Nov 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.70 |
- Benzinga
12 Biotech Stocks Primed For A Short Squeeze
Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...
- Zacks Small Cap Research
VKTX: Phase2b Trial of VK2809 Underway…
By David Bautz, PhD NASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update Phase 2b VOYAGE Trial Initiated On November 19, 2019, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced that the Phase 2b VOYAGE trial of VK2809 in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) is underway. The randomized, double blind, placebo-controlled trial is expected to enroll
- PR Newswire
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
SAN DIEGO, Nov. 19, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2b clinical trial of VK2809, its novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). Clinical trial sites are open for patient enrollment following clearance of the company's Investigational New Drug (IND) application by the United States Food and Drug Administration (FDA).
- Thomson Reuters StreetEvents
Edited Transcript of VKTX earnings conference call or presentation 5-Nov-19 1:30pm GMT
Q3 2019 Viking Therapeutics Inc Earnings Call
- PR Newswire
Viking Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO , Nov. 12, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
- Insider Monkey
Were Hedge Funds Right About Souring On Viking Therapeutics, Inc. (VKTX)?
Is Viking Therapeutics, Inc. (NASDAQ:VKTX) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
- Zacks Small Cap Research
VKTX: VK2809 IND Filed; P2b Trial to Initiate in 4Q19…
By David Bautz, PhD NASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update IND Filed for VK2809; P2b Trial to Initiate in 4Q19 On November 5, 2019, Viking Therapeutics, Inc. (NASDAQ:VKTX) provided a business update, which included the announcement that the Investigational New Drug (IND) application for VK2809 has been submitted to the FDA such that a Phase 2b clinical trial in patients
- GuruFocus.com
US Indexes Close Mostly Higher Tuesday
Dow Jones closes at a new record high of 27,492.63 Continue reading...
- PR Newswire
Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Conference call scheduled for 8:30 a.m. ET today - IND Application Filed for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH - Clinical Development of VK0214 for X-ALD Expected to Begin 1H20 - Balance ...
- PR Newswire
Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019
Conference Call Scheduled for Tuesday, November 5 at 8:30 a.m. Eastern Time SAN DIEGO , Oct. 31, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
- PR Newswire
Viking Therapeutics to Present at 2019 Cantor Global Healthcare Conference
SAN DIEGO , Sept. 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
- Simply Wall St.
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Motley Fool
Better Buy: Intercept Pharmaceuticals vs. Viking Therapeutics
The biotech rivals each aim to dominate the treatment market for non-alcoholic steatohepatitis (NASH).
- Motley Fool
3 Top Small-Cap Stocks to Buy in August
These small-cap stocks hold the potential to deliver big-time returns.
- Motley Fool
Is Viking Therapeutics a Buy?
What you need to know about this high-risk, high-reward biotech stock.
- Thomson Reuters StreetEvents
Edited Transcript of VKTX earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Viking Therapeutics Inc Earnings Call
Motley FoolViking Therapeutics Inc (VKTX) Q2 2019 Earnings Call Transcript
VKTX earnings call for the period ending June 30, 2019.
- Motley Fool
Where Will Viking Therapeutics Be in 1 Year?
It's one of the more promising companies in the race to develop a successful NASH treatment. Will patient investors be rewarded?
- Zacks Small Cap Research
VKTX: Awaiting Feedback from FDA regarding pre-IND submission; Phase 2b trial in NASH expected to initiate 2H19…
Viking Therapeutics, Inc. (VKTX) is currently preparing for the initiation of a Phase 2b clinical trial of VK2809, the company’s thyroid beta receptor (TRβ) agonist, for the treatment of nonalcoholic steatohepatitis (NASH). The company has submitted a pre-IND briefing package to the FDA and is currently awaiting written feedback.
- PR Newswire
Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today - Preparation for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Underway; Expect to Commence Enrollment in 2H19 - Continued Progress with VK0214 for ...
- Schaeffer's Investment Research
Options Traders Load Up On VKTX Calls Ahead of Earnings
Spread activity is detected today in VKTX's options pits
- PR Newswire
Viking Therapeutics to Report Financial Results for Second Quarter 2019 on August 1, 2019
Conference Call Scheduled for Thursday, August 1 at 4:30 p.m. Eastern Time SAN DIEGO , July 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
- Insider Monkey
Here’s What Hedge Funds Think About Viking Therapeutics, Inc. (VKTX)
Is Viking Therapeutics, Inc. (NASDAQ:VKTX) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
- Market Realist
How Viking Therapeutics Is Positioned
Viking Therapeutics (VKTX) stock closed at $7.98 on June 12, 2.70% higher than its previous close, 14.49% above its 52-week low of $6.97, and 66.75% below its 52-week high of $24.
